Get rewarded for investing more into Saebo:
Saebo is dedicated to bringing accessible, affordable, mobility solutions to all. Committed to “leaving no patient behind” Saebo sets out to create products that could benefit every patient. Saebo’s revolutionary product offering is based on the latest advances in rehabilitation research. From the SaeboFlex to the SaeboMAS, Saebo provides innovative and affordable rehabilitation products.
Saebo has grown into a leading global provider of rehabilitative products created through unrelenting leadership and a strong network of clinicians around the world. As we help over 600,000 clients regain function, we aim to make our newest products more accessible than ever.
The Problem
Every 2.1 seconds, someone in the world suffers a stroke. For those who are lucky enough to survive, overcoming paralysis can take months or even years of intense therapy.
Too often, patients are treated in facilities that do not offer the latest advances in stroke rehabilitation technology. Then, they are often sent home with no effective home program and without the tools and resources they need to recover. Most at home stroke rehabilitation technology is overpriced, ineffective, or too complicated for home use.
All along the way, doctors routinely misinform stroke patients about the potential for additional recovery. Many patients are told that they have reached a recovery “plateau” and additional progress is no longer possible.
Without help, patients experience worsening paralysis, decreased range-of-motion, increased pain and depression, and a deteriorating quality-of-life.
Making matters worse, even in developed countries like the U.S., insurance rarely covers the cost of long-term therapy or innovative rehabilitation products.
The latest research demonstrates that it doesn’t have to be this way. Today, we now know that recovery can continue for many years, even decades, but only if patients get the help they need.
The Solution
Saebo creates effective, safe, and affordable products allowing every patient to maximize their neurological recovery, from the clinic to the home.
Each of our exclusive, easy-to-use products is designed and vetted by experienced, practicing clinicians.
Our products are backed by years of clinical research and designed for simple use at home.
Our FDA approved and non-invasive devices are affordable, even to those without insurance coverage.
Our portfolio of products help stroke patients overcome a variety of impairments and maximize their recovery.
We have a product or service for every patient looking to improve their recovery at home.
And, because our products are guaranteed to be effective, affordable, and easy-to-use, patients can order any product on our website and enjoy a 30-Day Money-Back Guarantee. We also provide a free evaluation, expert advice, and follow-up clinical support with each order.
gif
Our Traction
Our lifetime net revenue is at over $44 million and we’ve seen tremendous growth to-date across our B2B and B2C sectors:
A distributor network spanning 6 continents and over 40 countries
17 Patents: our innovative product designs have been awarded 17 different patents by the US Patent Office
FDA clearance: our products has already satisfied FDA pre-marketing requirements or are regulated as class I devices, which are exempt from premarket requirements
Global adoption: Our products have been used by an estimated 800,000 patients in more than 4,000 hospitals around the world.
Additionally, our products are recommended by the 10 top rehabilitation hospitals in the US (as ranked by US News and World Report). Our products and treatment approaches have now been featured in 20 different medical textbooks and publications, authored by the top neurologists and professors around the world. Saebo products and programs are featured in numerous university curriculums around the world.
Our very first product, the SaeboFlex, was recently put on permanent display at the London Science Museum alongside other breakthrough medical technologies such as penicillin and the first MRI.
The Business Model
With over $44 million in net revenue to date, Saebo has a well-established multi-channel business model.
We sell products directly to the end-user through our D2C e-commerce platform. This platform leverages clinical expertise, producing educational content that generates over 250,000 website visits per month. This has paved the way for our significant digital footprint.
Another primary revenue stream is our B2B channel. We sell products directly to hospitals and treatment centers for use in the care of their patients.
We also sell our products through various domestic and international healthcare providers and medical product distributors. This hybrid approach leverages a wide network of international distributors, who can then leverage their insurance networks and/or provider networks to navigate local compliance and logistics issues.
We have seen steady growth to-date across all of these channels:
90% compound annual growth rate (CAGR) for products sold to US patients through our ecommerce platform since 2017.
27% compound annual growth rate (CAGR) for direct-to-patient unit product sales between 2013 and 2018.
10% compound annual growth rate (CAGR) for equipment sold to hospitals between 2013 and 2018.
And our multi-channel approach is now delivering scalable, capital-efficient growth opportunities based on falling customer acquisition costs and increasing customer lifetime values. Our current cost-per-acquisition is around $45 and our estimated lifetime value is about $300 per customer and rising.
The Market
Saebo is a well-established leader in the neurorehabilitation market for a significant population of stroke survivors:
Consistent, long-term growth in the worldwide market for stroke rehabilitation products will be driven by a number of factors including:
And finally, with COVID-19, we have seen an increased incidence of stroke. Particularly with pandemic restrictions, there is an increased urgency and demand for effective in-home therapy.
What we do
From hospital to home, our products and services support patients each step of the way. Our patient-targeted solutions are designed to meet three simple criteria:
We also devote many of our resources to educating patients and clinicians around the world about the latest advancements in treatment and how our products incorporate those treatment paradigms.
Saebo Academy is approved by the American Occupational Therapy Association to provide accredited continuing education courses to clinicians. To date, more than 20,000 therapists have participated in our educational programs worldwide.
Our technology and ever-expanding product base continue to grow, with 17 existing patents, demonstrating our unique and innovative technologies.
Saebo has been a worldwide leader in stroke rehabilitation since 2004 and continues to lead the way for patient recovery-focused solutions.
The Vision
At Saebo, we believe every patient deserves a helping hand. That means empowering patients with the education, tools, and financial assistance they need to take control of their own recovery.
Today, Saebo is considered by many to be the foremost leader in stroke rehabilitation. Tomorrow, we look forward to bringing our expertise to an ever-expanding range of neurological conditions and impairments.
The stroke survivor population is only the beginning. We also help treat veterans with traumatic brain injuries at VA centers across the country. Millions suffering from Multiple Sclerosis, neuropathy, and other neurological disorders could benefit from our technology.
OUR LEADERSHIP
With a combined 112 years of clinical experience and 49 years of management experience, the Saebo team is made up of exceptional leaders in business and medicine, poised to change the lives of patients around the world.
Why Invest
To continue to provide life-changing solutions for those suffering from impaired mobility and function, Saebo aims to expand global partnerships and provide directly accessible devices for every patient who needs them.
We hope to follow our momentum with funding from StartEngine for new product development, lower-cost product sourcing, a sophisticated DTP digital marketing platform, and additional domestic and international distribution channels and partners. We hope you will join the charge to provide innovative, affordable, and positively impactful solutions so that no patient is ever left behind.
gif
SaeboFlex supports Bradley Collins' wrist, allowing him to extend his left thumb and fingers in order to grasp and release objects.
The 27-year-old guitarist in popular indie band The Long Blondes hopes to play again despite suffering a stroke, thanks to cutting-edge medical technology.
Together, the SaeboMas Mini and the ArmeoSenso deliver an easy-to-use, compact solution at an affordable price.
Saebo's flagship product, SaeboFlex, included in the newly created Medicine Wellcome Galleries revealing break-through medical treatment innovations spanning the last 500 years.
Michael Seiler using the SaeboFlex during a rehabilitation session. After suffering a stroke in 2011, Seiler has put in years of hard work and continues to make progress with the Saebo equipment.
Hospital foundation raising funds for stroke rehabilitation equipment
Leader in unique, affordable technologies for individuals suffering from impaired mobility and function releases a virtual ADL system to maximize therapy outcomes.
Company | : | SAEBO, Inc. |
Corporate Address | : | 2459 Wilkinson Blvd. Ste 120-B, Charlotte, NC 28208 |
Offering Minimum | : | $10,000.00 |
Offering Maximum | : | $1,069,999.00 |
Minimum Investment Amount(per investor) | : | $248.00 |
Offering Type | : | Equity |
Security Name | : | Common Stock |
Minimum Number of Shares Offered | : | 20,000 |
Maximum Number of Shares Offered | : | 2,139,998 |
Price per Share | : | $0.50 |
Pre-Money Valuation | : | $10,964,387.50 |
*Maximum Number of Shares Offered subject to adjustment for bonus shares. See Bonus info below.
Votings Rights of Securities Sold in this Offering
Voting Proxy. Each Subscriber shall appoint the President of the Company (the “President”), or his or her successor, as the Subscriber’s true and lawful proxy and attorney, with the power to act alone and with full power of substitution, to, consistent with this instrument and on behalf of the Subscriber, (i) vote all Securities, (ii) give and receive notices and communications, (iii) execute any instrument or document that the President determines is necessary or appropriate in the exercise of its authority under this instrument, and (iv) take all actions necessary or appropriate in the judgment of the President for the accomplishment of the foregoing. The proxy and power granted by the Subscriber pursuant to this Section are coupled with an interest. Such proxy and power will be irrevocable. The proxy and power, so long as the Subscriber is an individual, will survive the death, incompetency and disability of the Subscriber and, so long as the Subscriber is an entity, will survive the merger or reorganization of the Subscriber or any other entity holding the Securities. However, the Proxy will terminate upon the closing of a firm-commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933 covering the offer and sale of Common Stock or the effectiveness of a registration statement under the Securities Exchange Act of 1934 covering the Common Stock.
Investment Incentives and Bonuses*
Time-Based:
Friends and Family Early Birds
Invest within the first 48 hours and receive an additional 20% bonus shares.
Super Early Bird Bonus
Invest within the first week and receive an additional 15% bonus shares.
Early Bird Bonus
Invest within the first two weeks and receive an additional 10% bonus shares.
Amount-Based:
$500+
Supporter Level
Supporters will receive a $25 gift card for the products or swag of your choice at saebo.com. You’ll also receive a personalized coupon code to save 20% on any product of your choice.*
$1,000+
Bronze Investor Level
Bronze Investors will receive a $50 gift card for the products or swag of your choice at saebo.com. You’ll also receive a coupon code to save 20% on your entire next order.*
$2,500+
Silver Investor Level
Silver Investors will receive a $100 gift card for the products or swag of your choice at saebo.com. You’ll also receive a personalized coupon code to save 20% on all of your orders for an entire year.*
$5,000+
Gold Investor Level
Gold Investors will receive 10% Bonus Shares plus all of the Silver Level perks. In addition, Saebo will donate, in your name, $500 worth of products to patients in need.
$10,000+
Platinum Investor Level
Platinum Investors will receive 15% Bonus Shares plus all of the Silver Level perks. In addition, Saebo will donate, in your name, $1,000 worth of products to patients in need.
*Excludes hospital-based treatment equipment (e.g., items priced over $5,000).
*All perks occur when the offering is completed.
The 10% StartEngine Owners' Bonus
Saebo, Inc. will offer 10% additional bonus shares for all investments that are committed by investors that are eligible for the StartEngine Crowdfunding Inc. OWNer's bonus.
This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of Common Stock at $0.50 / share, you will receive 110 shares of Common Stock, meaning you'll own 110 shares for $50. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.
This 10% Bonus is only valid during the investors eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are cancelled or fail.
Investors will only receive a single bonus, which will be the highest bonus rate they are eligible for.
A crowdfunding investment involves risk. You should not invest any funds in this offering unless you can afford to lose your entire investment. In making an investment decision, investors must rely on their own examination of the issuer and the terms of the offering, including the merits and risks involved. These securities have not been recommended or approved by any federal or state securities commission or regulatory authority. Furthermore, these authorities have not passed upon the accuracy or adequacy of this document. The U.S. Securities and Exchange Commission does not pass upon the merits of any securities offered or the terms of the offering, nor does it pass upon the accuracy or completeness of any offering document or literature. These securities are offered under an exemption from registration; however, the U.S. Securities and Exchange Commission has not made an independent determination that these securities are exempt from registration.
Kim Hook is an Occupational Therapist who has used Saebo’s products in her practice for ten years. Learn why she is such a fan of Saebo’s products and why she continues to believe in the company.
Disclaimer: "This testimonial may not be representative of the experience of other customers and is no guarantee of future performance or success.”
[The following is an automated notice from the StartEngine team].
Hello!
As you might know, Saebo has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in Saebo be on the lookout for an email that describes more about the disbursement process.
This campaign will continue to accept investments until its indicated closing date.
Thanks for funding the future.
-StartEngine
Saebo’s preliminary 4th quarter sales results are in, and despite the COVID-19 pandemic, our North American Patient orders are up a remarkable 13% versus Q4 prior year. This despite the fact that many of the rehabilitation facilities that refer Patient Products to us were closed, or on a very limited schedule for much of the year. Further, online orders of Patient Products through our shopping cart were up a whopping 53% for Q4 compared to Q4 2019, and up more than 50% for the full year, demonstrating the scalable nature of Saebo’s business model, and the continued strong demand for our Patient Products.
Saebo further reports that International orders, including Saebo’s wholly-owned UK subsidiary, were up 8% in Q4 2020 vs. Q4 2019. This is significant because many of Saebo’s large international markets (e.g., Germany, Italy, Benelux, UK, etc.) were also seriously impacted by COVID-19 shutdowns and restrictions in 2020.
“These significant increases, especially under the circumstances, highlight the company’s successful pivot in the face of COVID-19 related challenges to the US healthcare systems,” said Saebo’s President, Henry Hoffman. “By promoting and delivering our products directly to patients for in-home use, we’ve been able to help our customers around the world continue their recoveries at home while increasing the most important and fastest-growing segments of our business."
Check out this 30-second video of a UK client making remarkable gains over the holiday break with the SaeboGlove and SaeboMAS. The patient started with little hand movement. Watch how these products transformed his recovery.
The cutting-edge SaeboGlove supports a survivor’s affected hand while they move throughout their day. The SaeboGlove assists the patient with normal hand activities like grasping household items and rebuilds muscular strength in the process. The proprietary tension system extends the fingers and thumb after grasping. The SaeboGlove is based on the latest advances in neurorehabilitation research about the brain’s ability to “reprogram” itself through mass practice, task-oriented arm training.
The SaeboMAS, a zero-gravity arm support system, takes the weight off the shoulder and allows the arm to achieve the range of motion necessary for standard tasks and exercises. This, in turn, strengthens the muscles around the arm that would have otherwise gone unused. The SaeboMAS can assist with performing the prescribed repetitive motions that fight against joint pain, muscle spasticity, and weakness.
Thank you to our supporters! We reached our minimum raise in just 12 hours and now have over 130 new investors in Saebo! Here at Saebo, we are dedicated to bringing accessible, affordable, mobility solutions to all. We stay committed to “leaving no patient behind” and set out to create products that every patient can benefit from. If you have any questions about Saebo or our campaign, please feel free to leave us a comment below. Thank you!
Congratulations to Jeffrey Neal Isaac, Ph.D., our first Stroke Survivor to invest in Saebo. We want to thank all of our early investors and followers so far. Our vision is to help every patient, and there are about 79 million stroke survivors out there who could benefit from our solutions, just like our friend Jeffery did!
Disclaimer: "This testimonial may not be representative of the experience of other customers and is no guarantee of future performance or success.”
Comments ({{profileCtrl.startup.comments_count}} total)
{{ profileCtrl.commentsLoading ? 'Loading...' : 'Show More Comments' }}